Imlunestrant
Inluriyo · Oral selective estrogen-receptor degrader (SERD)
2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.
Voranigo · IDH1/2 inhibitor
Mutant IDH1/2 inhibitor · approved 2024 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is minimal. No vorasidenib-specific AKI signal has been reported; in the registrational INDIGO phase 3 trial the predominant grade >=3 toxicity was hepatic (ALT elevation in ~9.6%), not renal. A mild, reversible serum-creatinine increase — a transporter-mediated pseudo-AKI — is the expected renal finding. A precise renal-event incidence is not quantified.Source: 37272516
Any transporter-mediated creatinine rise appears early, within the first weeks to first cycles, then plateaus in a dose-related, stable fashion.
Distilled from: “A transporter-mediated creatinine rise, if it occurs, appears early (within the first weeks to first cycles) and plateaus; it is dose-related and stable rather than progressive.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Vorasidenib is an oral, blood-brain-barrier-penetrant inhibitor of the neomorphic mutant IDH1 (R132) and IDH2 (R172) enzymes. Mutant IDH converts alpha-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (D-2-HG), which dysregulates DNA and histone demethylation and blocks cellular differentiation. By suppressing D-2-HG production, vorasidenib restores epigenetic regulation and slows growth of IDH-mutant grade 2 gliomas, delaying progression and time to next intervention.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the Mutant IDH1/2 inhibitor class.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Jun 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dosage adjustment is recommended for patients with creatinine clearance (CL cr ) >40 mL/min. The pharmacokinetics and safety of vorasidenib in patients with CL cr ≤40 mL/min or renal impairment requiring dialysis have not been studied [see Clinical Pharmacology (12.3) ] . For patients with CL cr ≤40 mL/min or who require dialysis, monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] .
Kidney rows of the label's dosage tables
From the VORANIGO label (Jun 2026) · DailyMed
No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 612 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
12 of 612 reports
Reported with hospitalization
135 of 612 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Vorasidenib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Inluriyo · Oral selective estrogen-receptor degrader (SERD)
2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.
Hernexeos · HER2 TKI
HER2 exon20 TKI (2025); creatinine rise likely a secretion artifact.
Verzenio · CDK4/6 inhibitor
Benign creatinine rise via tubular secretion block.
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Tepmetko · MET inhibitor
Creatinine rise and peripheral edema.
Ojjaara · JAK/ACVR1 inhibitor
2023 myelofibrosis JAK inhibitor.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.